請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/4673
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 李文華 | |
dc.contributor.author | Chun-Kai Huang | en |
dc.contributor.author | 黃俊凱 | zh_TW |
dc.date.accessioned | 2021-05-14T17:45:03Z | - |
dc.date.available | 2020-09-25 | |
dc.date.available | 2021-05-14T17:45:03Z | - |
dc.date.copyright | 2015-09-25 | |
dc.date.issued | 2015 | |
dc.date.submitted | 2015-07-21 | |
dc.identifier.citation | Abbassi-Ghadi, N., Kumar, S., Huang, J., Goldin, R., Takats, Z., and Hanna, G. B. (2013). Metabolomic profiling of oesophago-gastric cancer: a systematic review. European journal of cancer 49, 3625-3637. 2. Allinen, M., Beroukhim, R., Cai, L., Brennan, C., Lahti-Domenici, J., Huang, H., Porter, D., Hu, M., Chin, L., Richardson, A., et al. (2004). Molecular characterization of the tumor microenvironment in breast cancer. Cancer cell 6, 17-32. 3. Ambrosini, G., Adida, C., and Altieri, D. C. (1997). A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3, 917-921. 4. Ammirante, M., Luo, J. L., Grivennikov, S., Nedospasov, S., and Karin, M. (2010). B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 464, 302-305. 5. Andarawewa, K. L., Motrescu, E. R., Chenard, M. P., Gansmuller, A., Stoll, I., Tomasetto, C., and Rio, M. C. (2005). Stromelysin-3 is a potent negative regulator of adipogenesis participating to cancer cell-adipocyte interaction/crosstalk at the tumor invasive front. Cancer research 65, 10862-10871. 6. Apte, R. N., Krelin, Y., Song, X., Dotan, S., Recih, E., Elkabets, M., Carmi, Y., Dvorkin, T., White, R. M., Gayvoronsky, L., et al. (2006). Effects of micro-environment- and malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour-host interactions. European journal of cancer 42, 751-759. 7. Baker, S. J., and Reddy, E. P. (1998). Modulation of life and death by the TNF receptor superfamily. Oncogene 17, 3261-3270. 8. Benton, C. R., Campbell, S. E., Tonouchi, M., Hatta, H., and Bonen, A. (2004). Monocarboxylate transporters in subsarcolemmal and intermyofibrillar mitochondria. Biochemical and biophysical research communications 323, 249-253. 9. Berclaz, G., Li, S., Price, K. N., Coates, A. S., Castiglione-Gertsch, M., Rudenstam, C. M., Holmberg, S. B., Lindtner, J., Erien, D., Collins, J., et al. (2004). Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 15, 875-884. 10. Bertini, I., Cacciatore, S., Jensen, B. V., Schou, J. V., Johansen, J. S., Kruhoffer, M., Luchinat, C., Nielsen, D. L., and Turano, P. (2012). Metabolomic NMR fingerprinting to identify and predict survival of patients with metastatic colorectal cancer. Cancer research 72, 356-364. 11. Bonuccelli, G., Tsirigos, A., Whitaker-Menezes, D., Pavlides, S., Pestell, R. G., Chiavarina, B., Frank, P. G., Flomenberg, N., Howell, A., Martinez-Outschoorn, U. E., et al. (2010). Ketones and lactate 'fuel' tumor growth and metastasis: Evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell cycle 9, 3506-3514. 12. Broer, S., Broer, A., Schneider, H. P., Stegen, C., Halestrap, A. P., and Deitmer, J. W. (1999). Characterization of the high-affinity monocarboxylate transporter MCT2 in Xenopus laevis oocytes. The Biochemical journal 341 ( Pt 3), 529-535. 13. Calle, E. E., Rodriguez, C., Walker-Thurmond, K., and Thun, M. J. (2003). Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. The New England journal of medicine 348, 1625-1638. 14. Catz, S. D., and Johnson, J. L. (2001). Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene 20, 7342-7351. 15. Chang, S. H., and Dong, C. (2007). A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses. Cell Res 17, 435-440. 16. Chen, J., Yao, Y., Gong, C., Yu, F., Su, S., Chen, J., Liu, B., Deng, H., Wang, F., Lin, L., et al. (2011). CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer cell 19, 541-555. 17. Cleary, M. P., and Grossmann, M. E. (2009). Minireview: Obesity and breast cancer: the estrogen connection. Endocrinology 150, 2537-2542. 18. Coussens, L. M., and Werb, Z. (2002). Inflammation and cancer. Nature 420, 860-867. 19. Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009). Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739-744. 20. Debnath, J., Muthuswamy, S. K., and Brugge, J. S. (2003). Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 30, 256-268. 21. Dirat, B., Bochet, L., Dabek, M., Daviaud, D., Dauvillier, S., Majed, B., Wang, Y. Y., Meulle, A., Salles, B., Le Gonidec, S., et al. (2011). Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. Cancer research 71, 2455-2465. 22. Dong, C. (2008). Regulation and pro-inflammatory function of interleukin-17 family cytokines. Immunol Rev 226, 80-86. 23. Drew, B. G., Hamidi, H., Zhou, Z., Villanueva, C. J., Krum, S. A., Calkin, A. C., Parks, B. W., Ribas, V., Kalajian, N. Y., Phun, J., et al. (2015). Estrogen receptor (ER)alpha-regulated lipocalin 2 expression in adipose tissue links obesity with breast cancer progression. The Journal of biological chemistry 290, 5566-5581. 24. Durocher, Y., Perret, S., and Kamen, A. (2002). High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res 30, E9. 25. Furuta, S., Jeng, Y. M., Zhou, L., Huang, L., Kuhn, I., Bissell, M. J., and Lee, W. H. (2011). IL-25 Causes Apoptosis of IL-25R-Expressing Breast Cancer Cells Without Toxicity to Nonmalignant Cells. Sci Transl Med 3, 78ra31. 26. Gerlinger, M., Santos, C. R., Spencer-Dene, B., Martinez, P., Endesfelder, D., Burrell, R. A., Vetter, M., Jiang, M., Saunders, R. E., Kelly, G., et al. (2012). Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target. The Journal of pathology 227, 146-156. 27. Gu, C., Castellino, A., Chan, J. Y., and Chao, M. V. (1998). BRE: a modulator of TNF-alpha action. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 12, 1101-1108. 28. Halestrap, A. P. (2012). The monocarboxylate transporter family--Structure and functional characterization. IUBMB Life 64, 1-9. 29. Halestrap, A. P. (2013). The SLC16 gene family - structure, role and regulation in health and disease. Molecular aspects of medicine 34, 337-349. 30. Halestrap, A. P., and Price, N. T. (1999). The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation. The Biochemical journal 343 Pt 2, 281-299. 31. Halestrap, A. P., and Wilson, M. C. (2012). The monocarboxylate transporter family--role and regulation. IUBMB Life 64, 109-119. 32. Hanahan, D., and Coussens, L. M. (2012). Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer cell 21, 309-322. 33. He, D., Li, H., Yusuf, N., Elmets, C. A., Li, J., Mountz, J. D., and Xu, H. (2010). IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells. J Immunol 184, 2281-2288. 34. Iida, T., Iwahashi, M., Katsuda, M., Ishida, K., Nakamori, M., Nakamura, M., Naka, T., Ojima, T., Ueda, K., Hayata, K., et al. (2011). Tumor-infiltrating CD4+ Th17 cells produce IL-17 in tumor microenvironment and promote tumor progression in human gastric cancer. Oncol Rep 25, 1271-1277. 35. Iwakura, Y., Ishigame, H., Saijo, S., and Nakae, S. (2011). Functional specialization of interleukin-17 family members. Immunity 34, 149-162. 36. Iyengar, P., Espina, V., Williams, T. W., Lin, Y., Berry, D., Jelicks, L. A., Lee, H., Temple, K., Graves, R., Pollard, J., et al. (2005). Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. The Journal of clinical investigation 115, 1163-1176. 37. Kaelin, W. G., Jr. (2011). Cancer and altered metabolism: potential importance of hypoxia-inducible factor and 2-oxoglutarate-dependent dioxygenases. Cold Spring Harbor symposia on quantitative biology 76, 335-345. 38. Kimijima, I., Ohtake, T., Sagara, H., Watanabe, T., and Takenoshita, S. (2000). Scattered fat invasion: an indicator for poor prognosis in premenopausal, and for positive estrogen receptor in postmenopausal breast cancer patients. Oncology 59 Suppl 1, 25-30. 39. Kirkham, B. W., Kavanaugh, A., and Reich, K. (2014). Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology 141, 133-142. 40. Kojima, Y., Acar, A., Eaton, E. N., Mellody, K. T., Scheel, C., Ben-Porath, I., Onder, T. T., Wang, Z. C., Richardson, A. L., Weinberg, R. A., and Orimo, A. (2010). Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proceedings of the National Academy of Sciences of the United States of America 107, 20009-20014. 41. Kryczek, I., Wei, S., Szeliga, W., Vatan, L., and Zou, W. (2009). Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 114, 357-359. 42. Kusano, A. S., Trichopoulos, D., Terry, K. L., Chen, W. Y., Willett, W. C., and Michels, K. B. (2006). A prospective study of breast size and premenopausal breast cancer incidence. International journal of cancer Journal international du cancer 118, 2031-2034. 43. Lee, I., Lee, S. J., Kang, W. K., and Park, C. (2012). Inhibition of monocarboxylate transporter 2 induces senescence-associated mitochondrial dysfunction and suppresses progression of colorectal malignancies in vivo. Molecular cancer therapeutics 11, 2342-2351. 44. Lee, J., Ho, W. H., Maruoka, M., Corpuz, R. T., Baldwin, D. T., Foster, J. S., Goddard, A. D., Yansura, D. G., Vandlen, R. L., Wood, W. I., and Gurney, A. L. (2001). IL-17E, a novel proinflammatory ligand for the IL-17 receptor homolog IL-17Rh1. J Biol Chem 276, 1660-1664. 45. Lin, R. Y., Vera, J. C., Chaganti, R. S., and Golde, D. W. (1998). Human monocarboxylate transporter 2 (MCT2) is a high affinity pyruvate transporter. The Journal of biological chemistry 273, 28959-28965. 46. Liotta, L. A., and Kohn, E. C. (2001). The microenvironment of the tumour-host interface. Nature 411, 375-379. 47. Locasale, J. W., Grassian, A. R., Melman, T., Lyssiotis, C. A., Mattaini, K. R., Bass, A. J., Heffron, G., Metallo, C. M., Muranen, T., Sharfi, H., et al. (2011). Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nature genetics 43, 869-874. 48. Lorincz, A. M., and Sukumar, S. (2006). Molecular links between obesity and breast cancer. Endocrine-related cancer 13, 279-292. 49. Losman, J. A., and Kaelin, W. G., Jr. (2013). What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev 27, 836-852. 50. Losman, J. A., Looper, R. E., Koivunen, P., Lee, S., Schneider, R. K., McMahon, C., Cowley, G. S., Root, D. E., Ebert, B. L., and Kaelin, W. G., Jr. (2013). (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 339, 1621-1625. 51. Lu, H., Ouyang, W., and Huang, C. (2006). Inflammation, a key event in cancer development. Mol Cancer Res 4, 221-233. 52. Ma, X. J., Hilsenbeck, S. G., Wang, W., Ding, L., Sgroi, D. C., Bender, R. A., Osborne, C. K., Allred, D. C., and Erlander, M. G. (2006). The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol 24, 4611-4619. 53. Ma, X. J., Wang, Z., Ryan, P. D., Isakoff, S. J., Barmettler, A., Fuller, A., Muir, B., Mohapatra, G., Salunga, R., Tuggle, J. T., et al. (2004). A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5, 607-616. 54. Maezawa, Y., Nakajima, H., Suzuki, K., Tamachi, T., Ikeda, K., Inoue, J., Saito, Y., and Iwamoto, I. (2006). Involvement of TNF receptor-associated factor 6 in IL-25 receptor signaling. J Immunol 176, 1013-1018. 55. Martin-Orozco, N., Muranski, P., Chung, Y., Yang, X. O., Yamazaki, T., Lu, S., Hwu, P., Restifo, N. P., Overwijk, W. W., and Dong, C. (2009). T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 31, 787-798. 56. McAllister, F., Bailey, J. M., Alsina, J., Nirschl, C. J., Sharma, R., Fan, H., Rattigan, Y., Roeser, J. C., Lankapalli, R. H., Zhang, H., et al. (2014). Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia. Cancer cell 25, 621-637. 57. Moasser, M. M. (2007). The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26, 6469-6487. 58. Nieman, K. M., Kenny, H. A., Penicka, C. V., Ladanyi, A., Buell-Gutbrod, R., Zillhardt, M. R., Romero, I. L., Carey, M. S., Mills, G. B., Hotamisligil, G. S., et al. (2011). Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nature medicine 17, 1498-1503. 59. Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., and Weinberg, R. A. (2005). Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121, 335-348. 60. Park, J., Morley, T. S., Kim, M., Clegg, D. J., and Scherer, P. E. (2014). Obesity and cancer--mechanisms underlying tumour progression and recurrence. Nat Rev Endocrinol 10, 455-465. 61. Paunescu, V., Bojin, F. M., Tatu, C. A., Gavriliuc, O. I., Rosca, A., Gruia, A. T., Tanasie, G., Bunu, C., Crisnic, D., Gherghiceanu, M., et al. (2011). Tumour-associated fibroblasts and mesenchymal stem cells: more similarities than differences. J Cell Mol Med 15, 635-646. 62. Pertega-Gomes, N., Vizcaino, J. R., Gouveia, C., Jeronimo, C., Henrique, R. M., Lopes, C., and Baltazar, F. (2013). Monocarboxylate transporter 2 (MCT2) as putative biomarker in prostate cancer. The Prostate 73, 763-769. 63. Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005). Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353, 1659-1672. 64. Pierobon, M., and Frankenfeld, C. L. (2013). Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis. Breast cancer research and treatment 137, 307-314. 65. Pinheiro, C., Albergaria, A., Paredes, J., Sousa, B., Dufloth, R., Vieira, D., Schmitt, F., and Baltazar, F. (2010). Monocarboxylate transporter 1 is up-regulated in basal-like breast carcinoma. Histopathology 56, 860-867. 66. Pinheiro, C., Longatto-Filho, A., Scapulatempo, C., Ferreira, L., Martins, S., Pellerin, L., Rodrigues, M., Alves, V. A., Schmitt, F., and Baltazar, F. (2008). Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas. Virchows Archiv : an international journal of pathology 452, 139-146. 67. Poff, A. M., Ari, C., Arnold, P., Seyfried, T. N., and D'Agostino, D. P. (2014). Ketone supplementation decreases tumor cell viability and prolongs survival of mice with metastatic cancer. International journal of cancer Journal international du cancer 135, 1711-1720. 68. Pollard, P. J., Briere, J. J., Alam, N. A., Barwell, J., Barclay, E., Wortham, N. C., Hunt, T., Mitchell, M., Olpin, S., Moat, S. J., et al. (2005). Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Human molecular genetics 14, 2231-2239. 69. Possemato, R., Marks, K. M., Shaul, Y. D., Pacold, M. E., Kim, D., Birsoy, K., Sethumadhavan, S., Woo, H. K., Jang, H. G., Jha, A. K., et al. (2011). Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 476, 346-350. 70. Rajala, M. W., and Scherer, P. E. (2003). Minireview: The adipocyte--at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 144, 3765-3773. 71. Reeves, P. J., Callewaert, N., Contreras, R., and Khorana, H. G. (2002). Structure and function in rhodopsin: high-level expression of rhodopsin with restricted and homogeneous N-glycosylation by a tetracycline-inducible N-acetylglucosaminyltransferase I-negative HEK293S stable mammalian cell line. Proc Natl Acad Sci U S A 99, 13419-13424. 72. Rickel, E. A., Siegel, L. A., Yoon, B. R., Rottman, J. B., Kugler, D. G., Swart, D. A., Anders, P. M., Tocker, J. E., Comeau, M. R., and Budelsky, A. L. (2008). Identification of functional roles for both IL-17RB and IL-17RA in mediating IL-25-induced activities. J Immunol 181, 4299-4310. 73. Rong, S., Bodescot, M., Blair, D., Dunn, J., Nakamura, T., Mizuno, K., Park, M., Chan, A., Aaronson, S., and Vande Woude, G. F. (1992). Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor. Molecular and cellular biology 12, 5152-5158. 74. Salomon, D. S., Brandt, R., Ciardiello, F., and Normanno, N. (1995). Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19, 183-232. 75. Sansone, P., Storci, G., Tavolari, S., Guarnieri, T., Giovannini, C., Taffurelli, M., Ceccarelli, C., Santini, D., Paterini, P., Marcu, K. B., et al. (2007). IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest 117, 3988-4002. 76. Sasser, A. K., Sullivan, N. J., Studebaker, A. W., Hendey, L. F., Axel, A. E., and Hall, B. M. (2007). Interleukin-6 is a potent growth factor for ER-alpha-positive human breast cancer. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 21, 3763-3770. 77. Schaffler, A., Scholmerich, J., and Buechler, C. (2007). Mechanisms of disease: adipokines and breast cancer - endocrine and paracrine mechanisms that connect adiposity and breast cancer. Nature clinical practice Endocrinology metabolism 3, 345-354. 78. Shi, Y., Ullrich, S. J., Zhang, J., Connolly, K., Grzegorzewski, K. J., Barber, M. C., Wang, W., Wathen, K., Hodge, V., Fisher, C. L., et al. (2000). A novel cytokine receptor-ligand pair. Identification, molecular characterization, and in vivo immunomodulatory activity. J Biol Chem 275, 19167-19176. 79. Shimazu, T., Hirschey, M. D., Newman, J., He, W., Shirakawa, K., Le Moan, N., Grueter, C. A., Lim, H., Saunders, L. R., Stevens, R. D., et al. (2013). Suppression of oxidative stress by beta-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science 339, 211-214. 80. Shultz, L. D., Lyons, B. L., Burzenski, L. M., Gott, B., Chen, X., Chaleff, S., Kotb, M., Gillies, S. D., King, M., Mangada, J., et al. (2005). Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 174, 6477-6489. 81. Siegel, R. L., Miller, K. D., and Jemal, A. (2015). Cancer statistics, 2015. CA: a cancer journal for clinicians 65, 5-29. 82. Singer, C. F., Kronsteiner, N., Hudelist, G., Marton, E., Walter, I., Kubista, M., Czerwenka, K., Schreiber, M., Seifert, M., and Kubista, E. (2003). Interleukin 1 system and sex steroid receptor expression in human breast cancer: interleukin 1alpha protein secretion is correlated with malignant phenotype. Clin Cancer Res 9, 4877-4883. 83. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182. 84. Son, J., Lyssiotis, C. A., Ying, H., Wang, X., Hua, S., Ligorio, M., Perera, R. M., Ferrone, C. R., Mullarky, E., Shyh-Chang, N., et al. (2013). Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 496, 101-105. 85. Sonveaux, P., Vegran, F., Schroeder, T., Wergin, M. C., Verrax, J., Rabbani, Z. N., De Saedeleer, C. J., Kennedy, K. M., Diepart, C., Jordan, B. F., et al. (2008). Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. The Journal of clinical investigation 118, 3930-3942. 86. Surmacz, E. (2007). Obesity hormone leptin: a new target in breast cancer? Breast cancer research : BCR 9, 301. 87. Tan, B., Qiu, Y., Zou, X., Chen, T., Xie, G., Cheng, Y., Dong, T., Zhao, L., Feng, B., Hu, X., et al. (2013). Metabonomics identifies serum metabolite markers of colorectal cancer. Journal of proteome research 12, 3000-3009. 88. Tang, G., Minemoto, Y., Dibling, B., Purcell, N. H., Li, Z., Karin, M., and Lin, A. (2001). Inhibition of JNK activation through NF-kappaB target genes. Nature 414, 313-317. 89. Taylor, M. A., Sossey-Alaoui, K., Thompson, C. L., Danielpour, D., and Schiemann, W. P. (2013). TGF-beta upregulates miR-181a expression to promote breast cancer metastasis. J Clin Invest 123, 150-163. 90. Tian, E., Sawyer, J. R., Largaespada, D. A., Jenkins, N. A., Copeland, N. G., and Shaughnessy, J. D., Jr. (2000). Evi27 encodes a novel membrane protein with homology to the IL17 receptor. Oncogene 19, 2098-2109. 91. Tyan, S. W., Hsu, C. H., Peng, K. L., Chen, C. C., Kuo, W. H., Lee, E. Y., Shew, J. Y., Chang, K. J., Juan, L. J., and Lee, W. H. (2012). Breast cancer cells induce stromal fibroblasts to secrete ADAMTS1 for cancer invasion through an epigenetic change. PloS one 7, e35128. 92. Tyan, S. W., Kuo, W. H., Huang, C. K., Pan, C. C., Shew, J. Y., Chang, K. J., Lee, E. Y., and Lee, W. H. (2011). Breast cancer cells induce cancer-associated fibroblasts to secrete hepatocyte growth factor to enhance breast tumorigenesis. PloS one 6, e15313. 93. van Harmelen, V., Skurk, T., and Hauner, H. (2005). Primary culture and differentiation of human adipocyte precursor cells. Methods in molecular medicine 107, 125-135. 94. Vargo-Gogola, T., and Rosen, J. M. (2007). Modelling breast cancer: one size does not fit all. Nature reviews Cancer 7, 659-672. 95. Vice, E., Privette, J. D., Hickner, R. C., and Barakat, H. A. (2005). Ketone body metabolism in lean and obese women. Metabolism: clinical and experimental 54, 1542-1545. 96. Vona-Davis, L., and Rose, D. P. (2007). Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocrine-related cancer 14, 189-206. 97. Wang, L., Yi, T., Kortylewski, M., Pardoll, D. M., Zeng, D., and Yu, H. (2009). IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 206, 1457-1464. 98. Wang, L., Yi, T., Zhang, W., Pardoll, D. M., and Yu, H. (2010). IL-17 enhances tumor development in carcinogen-induced skin cancer. Cancer Res 70, 10112-10120. 99. Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010). The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer cell 17, 225-234. 100. Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C. P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., and et al. (1995). Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3, 673-682. 101. Yamaguchi, J., Ohtani, H., Nakamura, K., Shimokawa, I., and Kanematsu, T. (2008). Prognostic impact of marginal adipose tissue invasion in ductal carcinoma of the breast. American journal of clinical pathology 130, 382-388. 102. Yang, J., Bielenberg, D. R., Rodig, S. J., Doiron, R., Clifton, M. C., Kung, A. L., Strong, R. K., Zurakowski, D., and Moses, M. A. (2009). Lipocalin 2 promotes breast cancer progression. Proceedings of the National Academy of Sciences of the United States of America 106, 3913-3918. 103. Yao, Z., Fanslow, W. C., Seldin, M. F., Rousseau, A. M., Painter, S. L., Comeau, M. R., Cohen, J. I., and Spriggs, M. K. (1995). Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity 3, 811-821. 104. Ye, H., Arron, J. R., Lamothe, B., Cirilli, M., Kobayashi, T., Shevde, N. K., Segal, D., Dzivenu, O. K., Vologodskaia, M., Yim, M., et al. (2002). Distinct molecular mechanism for initiating TRAF6 signalling. Nature 418, 443-447. 105. Zhang, S., Huang, W. C., Li, P., Guo, H., Poh, S. B., Brady, S. W., Xiong, Y., Tseng, L. M., Li, S. H., Ding, Z., et al. (2011). Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med 17, 461-469. 106. Zhang, W., Trachootham, D., Liu, J., Chen, G., Pelicano, H., Garcia-Prieto, C., Lu, W., Burger, J. A., Croce, C. M., Plunkett, W., et al. (2012). Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nature cell biology 14, 276-286. 107. Zhu, X., Mulcahy, L. A., Mohammed, R. A., Lee, A. H., Franks, H. A., Kilpatrick, L., Yilmazer, A., Paish, E. C., Ellis, I. O., Patel, P. M., and Jackson, A. M. (2008). IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines. Breast Cancer Res 10, R95. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/4673 | - |
dc.description.abstract | 癌症發展過程中,癌細胞除了自身細胞內調控影響外,也受周遭細胞影響。以癌細胞本身而言,癌細胞常常利用大量表現表面受體方式來增加自己生長與存活優勢。乳癌病人中大約有 20~25% 病人會大量表現第二型人類表皮生長因子受體 (HER2),這類病人可利用針對此受體之單株抗體-trastuzumab進行有效治療。然而目前除了 HER2 外,少有其他可應用於乳癌治療之專一標的被證實。在本論文中,我們證實細胞激素受體 IL-17RB 及其配體 IL-17B 對於乳癌癌化過程是重要的,此路徑活化亦可干擾正常乳腺上皮細胞乳腺發育過程,進而促進乳癌發展。 藉由受體 IL-17RB 及其配體 IL-17B結合,可活化下游轉錄因子 NF-κB,並進一步促進抑制細胞凋亡分子 Bcl-2表現,使癌細胞對於 Etoposide 細胞毒殺耐受性增加。另一方面,在乳癌病人臨床檢體中我們也觀察到 IL-17RB 與 HER2 表現量呈現正相關,同時大量表現 IL-17RB 與 HER2 的乳癌病人具有較差預後。在具trastuzumab 抗性之乳癌細胞中,抑制 IL-17RB 的表現亦可有效抑制其致癌性,顯示 IL-17RB 與 HER2 在乳癌細胞中可能扮演不同角色。當我們以 IL-17RB 與 IL-17B 中和性抗體對乳癌細胞進行處理後發現,無論是中和 IL-17RB 或 IL-17B 皆可有效抑制乳癌細胞致癌性,顯示 IL-17RB 與 IL-17B 在乳癌癌化過程中扮演重要角色,並具有可用來發展相對應治療方式之潛力。 另一方面,癌細胞與其微環境之交互作用對於癌症產生與發展過程亦扮演重要角色。乳腺組織中,脂肪細胞是間質細胞中比例最高的,臨床研究上也指出較大乳房女性具有較高乳癌危險因子。然而,目前對於脂肪細胞是如何影響乳癌發展則是未有定論。因此在本論文中,我們首先證實從乳癌病人乳房組織分離之脂肪細胞可促進某類乳癌細胞生長,此類細胞與雌激素受體之表現並無顯著相關性,暗示有其他重要路徑存在。透過cDNA微陣列與RNA干擾實驗結果交叉分析,我們發現 monocarboxylate transporter 2 (MCT2) 分子在對於脂肪細胞促進乳癌細胞生長過程中扮演重要角色。MCT2已知功能主要參與在酮體之一 β-hydroxybutyrate 由外而內之運輸。β-hydroxybutyrate 在細胞中可被做為內生性 HDAC 抑制劑,當我們以 β-hydroxybutyrate 處理具有 MCT2 表現之細胞時,可有效增加組蛋白 H3K9 位置的乙醯化,此位置目前被認為與基因表現呈現正相關。細胞經 β-hydroxybutyrate 處理後,可被誘導產生許多與促進癌細胞生長相關之因子表現,例如細胞激素 IL1β 與脂肪素 LCN2,進而促進乳癌細胞致癌性。同時,我們也觀察到在乳癌臨床檢體中,MCT2表現量與 IL1β 及 LCN2表現量具有高度正相關,並顯示較差預後。總結來說,在本研究中我們闡述了乳癌微環境中脂肪細胞如何與 MCT2 表現之乳癌細胞進行交互作用,進而促進乳癌發展。 | zh_TW |
dc.description.abstract | Cancer cells are not only regulated by autonomous signals, but also influenced by the surrounding cells. In the aspect of cancer cell-autonomous regulation, gain of function of membrane receptor is a good strategy exploited by cancer cells to benefit own growth and survival. Overexpression of HER2 has been served as a target for developing trastuzumab to treat 20~25% of breast cancer. However, little or none of other membrane receptor is found to be useful as potential target for breast cancer treatment since then. Here, we found that amplified signal of Interleukin-17 receptor B (IL-17RB) and its ligand IL-17B promoted tumorigenicity in breast cancer cells and impeded acinus formation in immortalized normal mammary epithelial cells. External signal transmitted through IL-17RB activated NF-κB to up-regulate anti-apoptotic factor Bcl-2 and induce etoposide resistance. Elevated expression of IL-17RB had a stronger correlation with poor prognosis than HER2 in breast cancer patients. Interestingly, breast cancer patients with high expression of IL-17RB and HER2 had the shortest survival rate. Depletion of IL-17RB in trastuzumab-resistant breast cancer cells significantly reduced their tumorigenic activity, suggesting that IL-17RB and HER2 play an independent role in breast carcinogenesis. Furthermore, treatment with antibodies specifically against IL-17RB or IL-17B effectively attenuated tumorigenicity of breast cancer cells. These results suggest that the amplified IL-17RB/IL-17B signal pathway may serve as a therapeutic target for developing treatment to manage IL-17RB associated breast cancer. The crosstalk between cancer cells and their microenvironments also contributes to cancer initiation and progression. Adipocyte is the most abundant cell type in mammary glands, and larger breast size is associated with an increased risk for breast cancer. However, how adipocytes in mammary gland affect breast cancer formation is not completely understood. Here, we showed that primary adipocytes derived from mammary glands promote malignant growth of distinct type of tumor cells independent of its status of estrogen receptor α (ER-α). Through differential microarray analyses and RNAi knockdown screening, monocarboxylate transporter 2 (MCT2), responsible for transporting β-hydroxybutyrate, a ketone body, was identified as a critical factor that mediated the promotion of tumorigenicity associated with the adipocytes. Treating MCT2-expressing breast cancer cells with β-hydroxybutyrate, a physiological HDAC inhibitor, increased histone H3K9 acetylation, a gene activation mark, up-regulated tumor-promoting genes including cytokine IL1β as well as adipokine lipocalin 2 (LCN2), and enhanced tumorigenic activity. Consistently, elevated expressions of MCT2 as well as IL1β and LCN2, were significantly correlated with poor prognosis in breast cancer patients. These results suggest a novel mechanism of a specific crosstalk between MCT-2-expressing cancer cells and β-hydroxybutyrate secreting adipocytes in mammary gland microenvironment for promoting breast cancer malignancy. | en |
dc.description.provenance | Made available in DSpace on 2021-05-14T17:45:03Z (GMT). No. of bitstreams: 1 ntu-104-D99442001-1.pdf: 85986962 bytes, checksum: 52d1442f79cb816e1762456b04b24c85 (MD5) Previous issue date: 2015 | en |
dc.description.tableofcontents | 中文摘要 I Abstract III 誌謝 V Table of contents VII Chapter I- Overview and rationale 1 Breast cancer 2 IL-17 family and tumorigenesis 4 Microenvironment of breast cancer cells 6 Fibroblast and breast tumorigenesis 7 Adipocytes and breast cancer 8 MCT2 (monocarboxylate transporter 2) 9 Chapter II- Autocrine/paracrine mechanism of Interleukin-17B receptor promotes breast tumorigenesis through NF-κB mediated anti-apoptotic pathway 12 Introduction 13 Materials and Methods 15 Results 22 Discussion 29 Figures and tables 32 Chapter III- β- hydroxybutyrate secreted from adipocytes in mammary glands promotes malignancy of breast cancer expressing monocarboxylate transporter 2 57 Introduction 58 Materials and Methods 60 Results 66 Discussion 74 Figures and tables 80 References 108 Curriculum vitae 123 Appendix 125 | |
dc.language.iso | en | |
dc.title | 細胞激素受體 IL-17RB 與乳腺脂肪細胞在乳癌癌化過程中所扮演之角色 | zh_TW |
dc.title | The roles of IL-17RB and mammary gland adipocytes in breast cancer tumorigenesis | en |
dc.type | Thesis | |
dc.date.schoolyear | 103-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 林敬哲,張明富,張智芬,李明學,莊立民 | |
dc.subject.keyword | 乳癌,細胞激素,脂肪細胞, | zh_TW |
dc.subject.keyword | breast cancer,tumorigenesis,IL-17RB,adipocytes, | en |
dc.relation.page | 125 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2015-07-21 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 生物化學暨分子生物學研究所 | zh_TW |
顯示於系所單位: | 生物化學暨分子生物學科研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-104-1.pdf | 83.97 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。